Search

Your search keyword '"Qian, Jianfei"' showing total 385 results
Start Over Author "Qian, Jianfei"
385 results on '"Qian, Jianfei"'

13. IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity

Author

Xiao, Liuling, Ma, Xingzhe, Ye, Lingqun, Su, Pan, Xiong, Wei, Bi, Enguang, Wang, Qiang, Xian, Miao, Yang, Maojie, Qian, Jianfei, and Yi, Qing

Subjects
Oncology, Experimental, Lipid peroxidation -- Research, T cells -- Health aspects -- Physiological aspects, STAT proteins -- Health aspects -- Physiological aspects, Immunotherapy -- Methods, Cancer -- Development and progression -- Genetic aspects -- Care and treatment -- Research, Interleukin-9 -- Health aspects -- Physiological aspects, Fatty acid metabolism -- Research, Oxidation-reduction reaction -- Research, Health care industry
Abstract

[CD8.sup.+] T cell longevity regulated by metabolic activity plays important roles in cancer immunotherapy. Although in vitropolarized, transferred IL-9-secreting [CD8.sup.+] Tc9 (cytotoxic T lymphocyte subset 9) cells exert greater persistence and antitumor efficacy than Tc1 cells, the underlying mechanism remains unclear. Here, we show that tumor-infiltrating Tc9 cells display significantly lower lipid peroxidation than Tc1 cells in several mouse models, which is strongly correlated with their persistence. Using RNA-sequence and functional validation, we found that Tc9 cells exhibited unique lipid metabolic programs. Tc9 cell-derived IL-9 activated STAT3, upregulated fatty acid oxidation and mitochondrial activity, and rendered Tc9 cells with reduced lipid peroxidation and resistance to tumor- or ROS-induced ferroptosis in the tumor microenvironment. IL-9 signaling deficiency, inhibiting STAT3, or fatty acid oxidation increased lipid peroxidation and ferroptosis of Tc9 cells, resulting in impaired longevity and antitumor ability. Similarly, human Tc9 cells also exhibited lower lipid peroxidation than Tc1 cells and tumor-infiltrating [CD8.sup.+] T cells expressed lower IL9 and higher lipid peroxidation- and ferroptosis-related genes than circulating [CD8.sup.+] T cells in patients with melanoma. This study indicates that lipid peroxidation regulates Tc9 cell longevity and antitumor effects via the IL-9/STAT3/fatty acid oxidation pathway and regulating T cell lipid peroxidation can be used to enhance T cell-based immunotherapy in human cancer., Introduction Adoptive cell transfer (ACT) is a highly personalized immunotherapy that utilizes ex vivo expansion and reinfusion of tumor-bearing-host lymphocytes to treat established cancers and has achieved great clinical success [...]

Published
2022
Full Text
View/download PDF

15. Supplementary Table 1 from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

17. Data from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

18. Data from p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

Author

He, Jin, primary, Liu, Zhiqiang, primary, Zheng, Yuhuan, primary, Qian, Jianfei, primary, Li, Haiyan, primary, Lu, Yong, primary, Xu, Jingda, primary, Hong, Bangxing, primary, Zhang, Mingjun, primary, Lin, Pei, primary, Cai, Zhen, primary, Orlowski, Robert Z., primary, Kwak, Larry W., primary, Yi, Qing, primary, and Yang, Jing, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

Author

He, Jin, primary, Liu, Zhiqiang, primary, Zheng, Yuhuan, primary, Qian, Jianfei, primary, Li, Haiyan, primary, Lu, Yong, primary, Xu, Jingda, primary, Hong, Bangxing, primary, Zhang, Mingjun, primary, Lin, Pei, primary, Cai, Zhen, primary, Orlowski, Robert Z., primary, Kwak, Larry W., primary, Yi, Qing, primary, and Yang, Jing, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Methods from p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

Author

He, Jin, primary, Liu, Zhiqiang, primary, Zheng, Yuhuan, primary, Qian, Jianfei, primary, Li, Haiyan, primary, Lu, Yong, primary, Xu, Jingda, primary, Hong, Bangxing, primary, Zhang, Mingjun, primary, Lin, Pei, primary, Cai, Zhen, primary, Orlowski, Robert Z., primary, Kwak, Larry W., primary, Yi, Qing, primary, and Yang, Jing, primary

Published
2023
Full Text
View/download PDF

32. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

Author

Qin, Hong, Lerman, Beatrisa, Sakamaki, Ippei, Wei, Guowei, Cha, Soungchul C., Rao, Sheetal S., Qian, Jianfei, Hailemichael, Yared, Nurieva, Roza, Dwyer, Karen C., Roth, Johannes, Yi, Qing, Overwijk, Willem W., and Kwak, Larry W.

Subjects
Tumors -- Analysis -- Health aspects -- Development and progression -- Genetic aspects -- Care and treatment -- Research, Immune response -- Physiological aspects -- Genetic aspects -- Research, Peptides -- Analysis -- Health aspects -- Physiological aspects -- Genetic aspects -- Research, Biological sciences, Health
Abstract

Immune evasion is an emerging hallmark of cancer progression. However, functional studies to understand the role of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment are limited by the lack of available specific cell surface markers. We adapted a competitive peptide phage display platform to identify candidate peptides binding MDSCs specifically and generated peptide-Fc fusion proteins (peptibodies). In multiple tumor models, intravenous peptibody injection completely depleted blood, splenic and intratumoral MDSCs in tumor-bearing mice without affecting proinflammatory immune cell types, such as dendritic cells. Whereas control Gr-1-specific antibody primarily depleted granulocytic MDSCs, peptibodies depleted both granulocytic and monocytic MDSC subsets. Peptibody treatment was associated with inhibition of tumor growth in vivo, which was superior to that achieved with Gr-1-specific antibody. Immunoprecipitation of MDSC membrane proteins identified S100 family proteins as candidate targets. Our strategy may be useful to identify new diagnostic and therapeutic surface targets on rare cell subtypes, including human MDSCs., Activating the immune system has emerged as a promising way to treat cancer. Recent successful phase 3 clinical trials of therapeutic cancer vaccines include the US Food and Drug Administration-approved [...]

Published
2014
Full Text
View/download PDF

37. Th9 cells promote antitumor immune responses in vivo

Author

Lu, Yong, Hong, Sungyoul, Li, Haiyan, Park, Jungsun, Hong, Bangxing, Wang, Lijuan, Zheng, Yuhuan, Liu, Zhiqiang, Xu, Jingda, He, Jin, Yang, Jing, Qian, Jianfei, and Yi, Qing

Subjects
CD8 lymphocytes -- Genetic aspects, Lung tumors -- Diagnosis -- Drug therapy, Immune response -- Genetic aspects, Interleukin-9 -- Dosage and administration, Health care industry
Abstract

Th9 cells are a subset of [CD4.sup.+] Th cells that produce the pleiotropic cytokine IL-9. IL-9/Th9 can function as both positive and negative regulators of immune response, but the role of IL-9/Th9 in tumor immunity is unknown. We examined the role of IL-9/Th9 in a model of pulmonary melanoma in mice. Lack of IL-9 enhanced tumor growth, while tumor-specific Th9 cell treatment promoted stronger antitumor responses in both prophylactic and therapeutic models. Th9 cells also elicited strong host antitumor [CD8.sup.+] CTL responses by promoting Ccl20/Ccr6-dependent recruitment of DCs to the tumor tissues. Subsequent tumor antigen delivery to the draining LN resulted in [CD8.sup.+] T cell priming. In agreement with this model, Ccr6 deficiency abrogated the Th9 cell-mediated antitumor response. Our data suggest a distinct role for tumor-specific Th9 cells in provoking [CD8.sup.+] CTL-mediated antitumor immunity and indicate that Th9 cell-based cancer immunotherapy may be a promising therapeutic approach., Introduction Identification of [CD4.sup.+] Th subsets has improved our understanding of adaptive immunity. Based on their cytokine secretion and immune regulatory function, Th cells include, but are not limited to, [...]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results